RHB-204
Pulmonary Nontuberculous Mycobacteria (NTM) Disease
Phase 3Active
Key Facts
Indication
Pulmonary Nontuberculous Mycobacteria (NTM) Disease
Phase
Phase 3
Status
Active
Company
About RedHill Biopharma
RedHill Biopharma is a publicly traded, Israel-based company dedicated to developing and commercializing novel, primarily oral, small-molecule drugs for significant unmet medical needs. Its strategy integrates in-house R&D with strategic acquisitions to build a portfolio focused on GI diseases, infectious diseases, and oncology. A key achievement is establishing a late-stage pipeline of host-directed oral antivirals designed as broad-spectrum, mutation-resistant medical countermeasures suitable for government stockpiling.
View full company profile